REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

NCT07594106 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

DRUG: REGN15505
DRUG: REGN15505+Cemiplimab
DRUG: REGN15505+REGN4336

Sponsor

Regeneron Pharmaceuticals